FDX2
Ferredoxin-2, mitochondrial
Also known as: FDX1L, FDX2_HUMAN, MGC19604
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6P4F2
- Gene
- FDX2
- Ensembl
- ENSG00000267673
- Chromosome
- 19
- Canonical length
- 183 aa
- Protein class
- Disease related genes, Predicted intracellular proteins
OverviewNCBI Gene
This gene encodes a member of the ferredoxin family. The encoded protein contains a 2Fe-2S ferredoxin-type domain and is essential for heme A and Fe/S protein biosynthesis. Mutation in FDX1L gene is associated with mitochondrial muscle myopathy. [provided by RefSeq, Sep 2014]
Canonical amino-acid sequenceUniProt
183 residues, UniProt reviewed canonical sequence.
>Q6P4F2|FDX2
1 MAASMARGGV SARVLLQAAR GTWWNRPGGT SGSGEGVALG TTRKFQATGS RPAGEEDAGG
61 PERPGDVVNV VFVDRSGQRI PVSGRVGDNV LHLAQRHGVD LEGACEASLA CSTCHVYVSE
121 DHLDLLPPPE EREDDMLDMA PLLQENSRLG CQIVLTPELE GAEFTLPKIT RNFYVDGHVP
181 KPHLocalizationUniProt · AlphaFold · HPA
Whether an antibody against FDX2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 77 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 77 nTPM
- amygdala: 62 nTPM
- hippocampal formation: 60 nTPM
- basal ganglia: 59 nTPM
- choroid plexus: 58 nTPM
- midbrain: 54 nTPM
Single-cell type
- neuroendocrine cells: 0.9 nCPM
- other brain neurons: 0.9 nCPM
- mucous neck cells: 0.8 nCPM
- brain excitatory neurons: 0.6 nCPM
- endometrial secretory cells: 0.6 nCPM
- epididymal basal cells: 0.5 nCPM
Immune cell
- NK-cell: 25 nTPM
- myeloid DC: 21 nTPM
- memory B-cell: 20 nTPM
- intermediate monocyte: 20 nTPM
- non-classical monocyte: 19 nTPM
- naive CD8 T-cell: 17 nTPM
Brain region
- white matter: 69 nTPM
- cerebral cortex: 57 nTPM
- hypothalamus: 55 nTPM
- hippocampal formation: 52 nTPM
- basal ganglia: 47 nTPM
- midbrain: 45 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about FDX2.
Disease | AllUniProt
Conditions FDX2 is implicated in, by any mechanism.
- Mitochondrial myopathy, episodic, with optic atrophy and reversible leukoencephalopathy (MEOAL) MIM:251900
Disease | GeneticClinVar
4 pathogenic / likely-pathogenic of 154 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Mitochondrial myopathy, episodic, with optic atrophy and reversible leukoencephalopathy
- Inborn mitochondrial myopathy
- Inborn genetic diseases
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.41
- gnomAD pLI
- 0
- DepMap mean gene effect
- -0.65
- DepMap dependency class
- common
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- [2Fe-2S] cluster assembly
- [4Fe-4S] cluster assembly
- electron transport chain
- iron-sulfur cluster assembly
- P450-containing electron transport chain
- ubiquinone biosynthetic process
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FDX2 as an antibody target. Whether an autoantibody or antibody against FDX2 could matter depends on whether native FDX2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FDX2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label FDX2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...